11-15-95 - Laserfiche WebLink

Home Browse Search

Strategic Alliances and Technology Licensing Agreements GalaGen has entered into a series of important strategic alliances and technology licensing agreements. Land O'Lakes GalaGen's agreements with Land O'Lakes provides for access to raw materials and the license of Land O'Lakes' technology developed prior to GalaGen's formation. Nestle Nestle has granted GalaGen a license to its technology relating to the production and use of bovine anti- rotavirus and anti-E. coli antibodies for therapeutic and prophylactic indications. The license includes Nestle's clinical data and foreign patents and also gives GalaGen the right to grant sublicenses. The license is exclusive in North America and semi-exclusive in the rest of the world. Chiron Corporation In March 1995 GalaGen and Chiron Corporation entered into a License and Collaboration Agreement, involving the licensing of Chiron adjuvant technology and a collaboration to research and develop passive immune therapies, using bovine antibodies, against H.pylori. Institut Pasteur Institut Pasteur granted GalaGen an exclusive license for an H.pylori antigen candidate. GalaGen has also entered into a collaborative research agreement that gives GalaGen rights to future technology emerging from the collaboration that relate to passive immunotherapy. United States Department of Agriculture The USDA granted GalaGen an exclusive license for a Cryptosporidium parvum antigen candidate, for both human and animal health applications. The license was granted for technology developed under a Cooperative Research and Development Agreement with the U.S.D.A. that was sponsored by GalaGen.